Overcoming the PDE5is paradigms with the 2nd generation therapeutic option

Industry session by THE MENARINI GROUP

  • Location:
    Room Amsterdam, North Hall (Level 1)
  • Chair:
     D. Hatzichristou, Thessaloniki (GR)
  • Aims and objectives of this session

    Erectile Dysfunction (ED) is a highly prevalent male sexual dysfunction and PDE5is are the well-known first line treatment for ED. After about 20 years since the first PDE5i has been released, several important pathophysiological and clinical issues can still be discovered about ED: answering to the question how many “users” believe that PDE5is will just improve their performance, while actually the drug is hiding their ED (and eventually comorbidities). How the different dosages fit with patient needs, how are they chosen, what can we learn and what outcome should be expected? The importance of the highest dosage from clinicians and patients perspective needs to be identified and deeply discussed and clarified.

    In this context Avanafil, a 2nd generation PDE5i, as a recent meta-analysis suggested, could represent, even at the highest dosage, a good choice in order to guarantee a lower drop-out and a better balance between efficacy and tolerability.

Introduction: ED 2017 status of the art - Are we still on the tip of the iceberg?
 D. Hatzichristou, Thessaloniki (GR)
ED users survey results from 7 European countries: New needs, patterns and therapeutic paradigms
 E.A. Jannini, Rome (IT)
The urologist perspective: When the highest dosage is the best starting choice
 I. Moncada, Madrid (ES)
The critical drop-out from first generation PDE5is: The importance of avanafil
 G. Corona, Bologna (IT)
Wrap up and closures
 D. Hatzichristou, Thessaloniki (GR)
Questions and answers